Drreddys Laboratories | RDY - Cash And Equivalent


Drreddys Laboratories reported INR15.37B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 360.21M 49.04M Jun/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Bayer EUR 4.29B 1.44B Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Cipla INR 10.18B 2.22B Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Drreddys Laboratories INR 15.37B 3.29B Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lonza CHF 719M 188M Dec/2025
Novartis USD 7.62B 739M Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Phibro Animal Health USD 61.42M 6.49M Jun/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Richter Gedeon HUF 135.63B 61.59B Dec/2024
Sun Pharmaceuticals INR 97.71B 15.61B Mar/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026